Entity

Time filter

Source Type

CABA, Argentina

Perez-Millan M.I.,CONICET | Berner S.I.,Servicio de Neurocirugia | Luque G.M.,CONICET | De Bonis C.,Servicio de Neurocirugia | And 3 more authors.
Pituitary | Year: 2013

The role of angiogenesis in human pituitary tumor progression is questioned. Our aim was to characterize the morphologic changes that occur in the vasculature of pituitary adenomas, in correlation with the expression of nestin, a protein found in endothelial cells of newly formed vessels of developing organs. We also evaluated the relation of angiogenic markers and nestin with Ki-67 index. Immunohistochemical studies were performed on paraffin embedded samples of 47 pituitary adenomas and six normal pituitaries. We determined microvessel density (number of CD31+ or CD34+ vessels per square millimetre), vascular area (cumulative area occupied by vessels), average vessel size, and further classified vessels as small (<100 μm2) or large (>100 μm2). We correlated the above parameters with nestin expression and Ki-67 index. Lower vascular area compared to normal tissue was found in adenomas (p < 0.05). Interestingly, pituitary adenomas had significantly more small vessels than control pituitaries (p < 0.04 for CD31 and CD34). In tumors many capillaries were positive for nestin, while scarce staining was detected in controls, so that nestin positive area was significantly higher in tumors. Furthermore, nestin area correlated positively with the % of small vessels. Ki-67 correlated neither with vascular area nor with nestin expression. In human pituitary tumors there was a predominance of small capillaries in correlation with increased expression of the progenitor marker nestin. We suggest that angiogenesis is an active process in these tumors, in spite of their low total vascular area when compared to normal pituitaries. © 2012 Springer Science+Business Media, LLC. Source


Filippatos G.,National and Kapodistrian University of Athens | Khan S.S.,Northwestern University | Ambrosy A.P.,Duke University | Cleland J.G.F.,Imperial College London | And 14 more authors.
European Journal of Heart Failure | Year: 2015

Aims The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF (International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure) is a global, prospective, and observational study designed to characterize patient trajectories longitudinally during and following an index hospitalization for HF. Methods Data collection for the registry will be conducted at ?300 sites located in ?40 countries. Comprehensive data including demographics, clinical presentation, co-morbidities, treatment patterns, quality of life, in-hospital and post-discharge outcomes, and health utilization and costs will be collected. Enrolment of ?20 000 adult patients hospitalized with new-onset (first diagnosis) HF or decompensation of chronic HF over a 3-year period is planned with subsequent 3 years follow-up. Perspective The REPORT-HF registry will explore the clinical characteristics, management, and outcomes of HF worldwide. This global research programme may have implications for the formulation of public health policy and the design and conduct of international clinical trials. © 2015 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. Source


Perrone S.V.,Instituto FLENI | Perrone S.V.,Instituto Argentino Of Diagnostico Y Tratamiento | Perrone S.V.,Instituto Cardiovascular Lezica
Insuficiencia Cardiaca | Year: 2014

This review is a compilation of the History of Medicine in Heart Failure that we will present in four chapters during the current year. They will describe the efforts of medicine and related sciences to combat this serious problem which is the end point of almost all cardiovascular pathologies. Our objective is to try to correlate in this document the history of different pathophysiological and therapeutic models of heart failure and its evolution to the present in an inseparable way to the History of Medicine and, particularly, to the History of Cardiology. © 2014 Silver Horse. Source


Bevacqua R.J.,Pabellon Inchauspe | Perrone S.V.,Instituto FLENI | Perrone S.V.,Instituto Argentino Of Diagnostico Y Tratamiento | Perrone S.V.,Instituto Cardiovascular Lezica
Insuficiencia Cardiaca | Year: 2013

Over the last decade has witnessed extensive progress in basic and clinical research in the field of pulmonary arterial hypertension (PAH). International PAH registries have achieved much to advance our understanding of the epidemiology, demographics, etiology, clinical course, hemodynamics, disease management and treatment outcomes of PAH. Therapies available to target the pathophysiology of PAH have expanded considerably and more options are expected in the near future. However, the long-term prognosis for patients with PAH remains poor. Recent evidence suggests that World Health Organization functional (WHO) class I or II patients have significantly better long-term survival rates than WHO functional class III-IV patients, thus providing a rationale for earlier diagnosis and treatment of PAH. However, early diagnosis is challenging and there is frequently a delay between symptom onset and diagnosis. Screening programs have an important role in PAH detection and expert opinion favours echocardiographic screening of asymptomatic patients who may be predisposed to the development of PAH. © 2013 Silver Horse. Source


Bevacqua R.J.,Pabellon Inchauspe | Bortman G.,Insuficiencia cardiaca | Perrone S.V.,Instituto FLENI | Perrone S.V.,Instituto Argentino Of Diagnostico Y Tratamiento | Perrone S.V.,Instituto Cardiovascular Lezica
Insuficiencia Cardiaca | Year: 2013

Pulmonary arterial hypertension (PAH) is a consequence of acute or chronic disorder of the pulmonary vasculature, which is characterized by increased pulmonary artery pressure as a result of increased pulmonary vascular resistance. The pathophysiology of PAH is characterized by pulmonary vascular vasoconstriction, smooth muscle cell proliferation, and thrombosis. These changes are a result of an imbalance between vasodilators (prostacyclin, nitric oxide, vasoactive intestinal peptide) and vasoconstrictors (thromboxane A2, endothelin, serotonin), growth inhibitors and mitogenic factors, and antithrombotic and prothrombotic factors. Recent advances in treatment are directed at restoring the balance between these systems. Endothelin receptor antagonists (bosentan, ambrisentan), phosphodiesterase type 5 inhibitors (sildenafil, tadalafil), and prostacylin (epoprostenol, iloprost, treprostinil, beraprost) represent the different classes of medications that are currently used in monotherapy and in combination to treat PAH. The purpose of this review is to provide the reader with an update on the treatment of PAH with antagonists of endothelin receptors. © 2013 Silver Horse. Source

Discover hidden collaborations